SCHEMBL4201979

SCHEMBL4201979

CCOC(=O)Nc1cccc(COS(C)(=O)=O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.56
LMNA P02545 1/20 0.56
MAPT P10636 1/20 0.56
HSD17B10 Q99714 1/20 0.56
ALDH1A1 P00352 1/20 0.53
PARP1 P09874 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 3/20 0.49
HTT P42858 2/20 0.49
F2R P25116 1/20 0.49
CYP2C9 P11712 3/20 0.48
CYP2C19 P33261 3/20 0.48
CYP2D6 P10635 2/20 0.48
TSHR P16473 1/20 0.48
MGLL Q99685 1/20 0.48
MTNR1B P49286 1/20 0.47
HPGD P15428 2/20 0.46
CYP1A2 P05177 2/20 0.46
RAB9A P51151 2/20 0.46
MET P08581 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6210649 0.87 MAPK1 (0.53) MAPK1LMNAMAPTHSD17B10ALDH1A1
SCHEMBL19720235 0.83 ALDH1A1 (0.53) LMNAHSD17B10ALDH1A1NPC1TSHR
SCHEMBL1025076 0.83 SIRT2 (0.48) CYP2C19HDAC3HDAC1HDAC2HDAC8
SCHEMBL21349100 0.82 MAPK1 (0.66) MAPK1LMNAMAPTHSD17B10ALDH1A1
SCHEMBL4197894 0.80 MAPK1 (0.64) MAPK1LMNAMAPTHSD17B10ALDH1A1
SCHEMBL7475224 0.80 MAPK1 (0.64) MAPK1LMNAMAPTHSD17B10ALDH1A1
SCHEMBL7565149 0.80 MAPK1 (0.81) MAPK1LMNAMAPTHSD17B10ALDH1A1
SCHEMBL4129269 0.79 MAPK1 (0.62) MAPK1LMNAMAPTHSD17B10ALDH1A1
SCHEMBL8867305 0.78 MAPT (0.61) MAPK1LMNAMAPTHSD17B10ALDH1A1
SCHEMBL6212581 0.78 MAPK1 (0.61) MAPK1LMNAMAPTHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090005364-A1 Azole Derivatives With Antimuscarinic Activity CHIESI FARMACEUTICI S.P.A. (IT) 2009-01-01 US disclosed
EP-1828163-A2 AZOLE DERIVATIVES WITH ANTIMUSCARINIC ACTIVITY CHIESI FARMACEUTICI S.p.A. (IT) 2007-09-05 EP disclosed
WO-2006066924-A2 AZOLE DERIVATIVES WITH ANTIMUSCARINIC ACTIVITY CHIESI FARMACEUTICI S.P.A. (IT) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005364-A1 Azole Derivatives With Antimuscarinic Activity CHRM2, CHRM3, CHRM1 MAPK1 1929/4885LMNA 2821/4885MAPT 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.